Asuragen Sets Sights on Pancreatic Cancer Screen Through TGen Collaboration
April 22, 2010
Asuragen Sets Sights on Pancreatic Cancer Screen Through TGen Collaboration
Terms of the arrangement, which marks Asuragen's first effort to develop an miRNA screen in a clinical setting, call for the partners to study blood samples from healthy individuals and patients with pancreatic abnormalities and pancreatic cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Asuragen Publishes Details about miRNA Pancreatic Cancer Test, Stresses Importance of Validation Process
April 21, 2011 / Gene Silencing News - Asuragen Launches FNA Version of microRNA Pancreatic Cancer Diagnostic
February 23, 2012 / Gene Silencing News - Asuragen Presents Data on miRNA Tests for Pancreatic Cancer
November 10, 2011 / Gene Silencing News - TGen to Partner with Asuragen on Cancer Dx
April 16, 2010 / GenomeWeb Daily News - Asuragen Forms Collaborations to Develop FNA Version of Pancreatic Cancer miRNA Test
February 4, 2010 / Gene Silencing News